Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT05811663 Completed - Fibromyalgia Clinical Trials

Health Care Use and Costs of Functional Somatic Disorders

Start date: November 10, 2011
Phase:
Study type: Observational

The goal of this observational case-control study is to learn about direct healthcare use and costs of functional somatic disorders. The aim of the proposed study is to investigate the use and costs of direct healthcare for individuals with functional somatic disorders. Researchers will compare direct healthcare use and costs of individuals with functional somatic disorders and compare them with that of healthy controls and individuals with other severe physical disease, respectively.

NCT ID: NCT05811130 Completed - Clinical trials for Premenstrual Syndrome

Premenstrual Syndrome and Its Influencing Factors Such as Physical Activity, Perceived Stress and Mental Status

Start date: June 1, 2021
Phase:
Study type: Observational

Our research aimed to investigate how a sedentary lifestyle, body mass index, depression, and stress affect the severity of PMS symptoms and how the listed factors influence each other.

NCT ID: NCT05809323 Recruiting - Marfan Syndrome Clinical Trials

Marfan Syndrome Moderate Exercise Trial II

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Marfan syndrome (MFS) is a distinctive connective tissue disorder that affects multiple organ systems including the heart, bones, ligaments, and eyes, and is associated with significant risk of aortic dissection. Given limited evidence from in-vitro studies, and theoretical concerns, the majority of patients with MFS are restricted from certain physical activities. The lack of exercise and deconditioning have detrimental effects including increasing weakness, joint pain, decreased endurance, and depressive symptoms. Given the significant paucity of data currently existing on the effects of exercise in humans with MFS, and the recent, optimistic findings in rodent models, this pilot trial was established to assess the effects of moderated dynamic exercise in adolescents and young adults with MFS.

NCT ID: NCT05808023 Recruiting - Clinical trials for Irritable Bowel Syndrome

Dose-dependent FODMAP Reintroduction in IBS

DORI
Start date: April 2023
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate whether symptom recurrence, after successful FODMAP elimination, is dose-dependent in patients with IBS. The effect of a blinded reintroduction of FODMAP powders fructans and mannitol will be investigated in a crossover dose-escalation scheme for the identification of the eliciting dose in individual patients. The reintroduction of FODMAPs is performed after a successful elimination by the LFD.

NCT ID: NCT05807919 Recruiting - Clinical trials for Irritable Bowel Syndrome

Evaluating the Efficacy of the Mediterranean Diet to the Low- Fermentable, Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAP) Diet in Treating Irritable Bowel Syndrome(IBS)

Start date: April 10, 2023
Phase: N/A
Study type: Interventional

This study is being completed to determine if the Mediterranean (MD) and low FODMAP (fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols) diets are comparable in the effectiveness to treat Irritable Bowel Syndrome (IBS). The study team hypothesizes that: - The low FODMAP and Mediterranean groups will achieve a similar improvement in abdominal pain - Both groups will achieve similar improvements in bloating, overall IBS symptom severity, and adequate relief

NCT ID: NCT05805605 Recruiting - Clinical trials for Myelodysplastic Syndromes

Allo HSCT Using RIC and PTCy for Hematological Diseases

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.

NCT ID: NCT05805566 Recruiting - Post-Covid Syndrome Clinical Trials

Retrospective and Prospective Cohort of Patients Entering the Multidisciplinary Management of Post-Covid Syndromes

SyPoCo
Start date: April 27, 2023
Phase:
Study type: Observational [Patient Registry]

SARS-CoV2 pneumonia has been a global public health emergency since 2020. The prevalence of the disease is particularly high with more than 500 million cases worldwide (7.5 million in France) since the emergence of the virus. A substantial proportion of patients with SARS-Cov2 infection present persistent symptoms long after the acute infection. This is independent of the degree of severity of the SARS-Cov2 infection. These symptoms can affect the quality of life and impede the return to work. While the majority of symptoms progress favourably with outpatient care, some persist and/or are particularly severe, justifying expert and multidisciplinary care. This investigation aim to create a clinical database of patients with complex and/or severe post-CoviD and study blood markers what could predict the disease and orientate new ways of treatment.

NCT ID: NCT05805293 Not yet recruiting - Clinical trials for Obesity Hypoventilation Syndrome (OHS)

HVNI Versus NIV In Management Of Acute Hypercapnic Respiratory Failure In OHS

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

1. Assessment of benefits of HVNI in management of obesity hypoventilation syndrome complicated with acute hypercapnic respiratory failure. 2. Compare the value, safety and effectiveness of HVNI and NIV in patients with obesity hypoventilation syndrome complicated with acute hypercapnic respiratory failure.

NCT ID: NCT05804669 Recruiting - Cushing Syndrome Clinical Trials

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Start date: October 12, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone [ACTH] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome [EAS])

NCT ID: NCT05803993 Recruiting - Clinical trials for Irritable Bowel Syndrome

Fecal Microbiota Transplantation to Relieve Symptoms of Irritable Bowel Syndrome With Constipation

TRAMIR-S
Start date: December 23, 2021
Phase: N/A
Study type: Interventional

Irritable bowel syndrome (IBS) is a complex multifactorial functional disorder, whose pathophysiology is largely associated to an impairment of the intestinal microbiota composition, namely dysbiosis. Thus, the modulation of the gut microbiota has been proposed as a possible therapeutic strategy for IBS patients alongside with current available drugs. Fecal microbiota transplantation (FMT) is a promising strategy to restore intestinal eubiosis. In this randomised double-blind placebo-controlled trial patients diagnosed with IBS with constipation are assigned with 1:1 ratio to receive FMT from healthy donor or autologous FMT (placebo group) to assess the effectiveness of FMT on IBS symptoms and quality of life, to evaluate the safety of FMT among IBS patients and to estimate any change in the gut microbiota composition of IBS patients after the FMT.